In order to measure the effectiveness of new therapies a technique is needed which can measure quantitatively in vivo pathology. In cardiology, the introduction of thrombolytic agents, which lyse the initial thrombus, has given added stimulus to the search for techniques which would fill this role. In this paper the extent to which nuclear medicine and magnetic resonance imaging can meet the requirements is discussed.